We are live on !
Find out more
VMI
VHCP Management II Portfolio holdings
AUM
$379M
Turnover
58.62%
1-Year Est. Return
421.62%
This Fund
S&P 500
This Quarter Est. Return
+255.77%
1 Year Est. Return
+421.62%
3 Year Est. Return
+2,333.62%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$379M
AUM Growth
+$117M
(+45%)
Cap. Flow
-$59M
Cap. Flow % of AUM
Cap. Flow %
-15.54%
Top 10 Holdings %
Top 10 Hldgs %
94.12%
Holding
29
New
8
Increased
1
Reduced
7
Closed
9
Avg Time Held
0.8
years
Top 10 Avg Time Held
0.7
years
Top 20 Avg Time Held
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
+$22.3M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$3.59M |
| 3 |
Relmada Therapeutics
RLMD
|
+$3.49M |
| 4 |
Adverum Biotechnologies
ADVM
|
+$3.38M |
| 5 |
Mersana Therapeutics
MRSN
|
+$2.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$22.6M |
| 2 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
+$16M |
| 3 |
Shockwave Medical, Inc. Common Stock
SWAV
|
+$13.2M |
| 4 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$12.4M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
+$8.24M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
10x Genomics
TXG
$9.11B
| $136M | 35.91% |
1,786,431
| – | – |
2019 Q3
1 quarter
|
|
2
Axsome Therapeutics
AXSM
$8.16B
| $81.2M | 21.42% |
785,981
-106,965
| -12% | -$4.32M |
2019 Q1
3 quarters
|
|
|
CNST
3
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $70.7M | 18.64% |
1,500,631
+773,954
| +107% | +$22.3M |
2018 Q3
5 quarters
|
|
|
4
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $25.2M | 6.64% |
462,903
-250,000
| -35% | -$12.4M |
2017 Q2
10 quarters
|
|
|
5
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $12.7M | 3.34% |
288,838
-357,589
| -55% | -$13.2M |
2019 Q1
3 quarters
|
|
|
ISEE
6
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $8.62M | 2.27% |
+1,004,299
| New | +$3.59M |
2019 Q4
0 quarters
|
|
7
DELISTED
KalVista Pharmaceuticals
KALV
| $6.52M | 1.72% |
366,268
-10,621
| -3% | -$139K |
2018 Q3
5 quarters
|
|
|
OBSV
8
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $6.01M | 1.58% |
1,573,639
-678,821
| -30% | -$3.53M |
2017 Q2
10 quarters
|
|
|
9
DELISTED
Mersana Therapeutics
MRSN
| $5.29M | 1.39% |
+36,901
| New | +$2.7M |
2019 Q4
0 quarters
|
|
10
Spero Therapeutics
SPRO
$65.2M
| $4.56M | 1.2% |
474,015
| – | – |
2017 Q4
8 quarters
|
|
|
11
Relmada Therapeutics
RLMD
$337M
| $4.48M | 1.18% |
+114,876
| New | +$3.49M |
2019 Q4
0 quarters
|
|
|
12
DELISTED
Adverum Biotechnologies
ADVM
| $4.42M | 1.16% |
+38,362
| New | +$3.38M |
2019 Q4
0 quarters
|
|
13
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $3.21M | 0.85% |
371,669
| – | – |
2018 Q2
6 quarters
|
|
|
FTSV
14
DELISTED
Forty Seven, Inc. Common Stock
FTSV
| $3.06M | 0.81% |
+77,714
| New | +$1.25M |
2019 Q4
0 quarters
|
|
15
Milestone Pharmaceuticals
MIST
$87.2M
| $2.38M | 0.63% |
148,560
| – | – |
2019 Q2
2 quarters
|
|
16
NextCure
NXTC
$26M
| $2.04M | 0.54% |
+3,021
| New | +$1.52M |
2019 Q4
0 quarters
|
|
|
MYOV
17
DELISTED
Myovant Sciences Ltd.
MYOV
| $1.19M | 0.31% |
+76,768
| New | +$774K |
2019 Q4
0 quarters
|
|
18
DELISTED
89bio
ETNB
| $1.08M | 0.29% |
+41,235
| New | +$1.15M |
2019 Q4
0 quarters
|
|
|
BLPH
19
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
| $230K | 0.06% |
43,939
-232,686
| -84% | -$1.48M |
2017 Q3
9 quarters
|
|
20
Protagonist Therapeutics
PTGX
$8.7B
| $227K | 0.06% |
32,211
-394,570
| -92% | -$3.92M |
2018 Q4
4 quarters
|
|
|
21
Ascendis Pharma A/S
ASND
$15.1B
| – | – |
-234,591
| Closed | -$22.6M | – |
|
|
22
BioCryst Pharmaceuticals
BCRX
$2.06B
| – | – |
-2,874,602
| Closed | -$8.24M | – |
|
23
Kiniksa Pharmaceuticals
KNSA
$6.2B
| – | – |
-540,461
| Closed | -$4.6M | – |
|
24
DELISTED
Kineta, Inc. Common Stock
KA
| – | – |
-934
| Closed | -$110K | – |
|
|
TCDA
25
DELISTED
Tricida, Inc. Common Stock
TCDA
| – | – |
-118,886
| Closed | -$3.67M | – |
|
Similar funds
ACPU
PI
SC
FFSOTS
PC
WC
VOAM
LB
VHCP Management II's Q4 2019 Portfolio in Review
As of Q4 2019, VHCP Management II held 29 positions worth $379M, up 45% from $262M the previous quarter. Its ten largest holdings account for 94% of the portfolio.
VHCP Management II withdrew a net $59M in Q4 2019, closing 9 positions and reducing 7 holdings. Its most notable exit was Ascendis Pharma A/S, an estimated $22.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, VHCP Management II opened a new position in IVERIC bio, Inc. Common Stock worth $8.62M.
- VHCP Management II's largest Q4 2019 buy was IVERIC bio, Inc. Common Stock: 1,004,299 shares worth $8.62M.
- VHCP Management II added most to Constellation Pharmaceuticals, Inc. in Q4 2019, an estimated $22.3M increase.
- VHCP Management II's biggest Q4 2019 reduction was Shockwave Medical, Inc. Common Stock, cutting an estimated $13.2M.
- VHCP Management II fully exited Ascendis Pharma A/S in Q4 2019, selling an estimated $22.6M.
- VHCP Management II's ten largest holdings make up 94% of its $379M portfolio in Q4 2019.
- VHCP Management II opened 8 new positions and closed 9 in Q4 2019.
- VHCP Management II's portfolio value rose 45% quarter-over-quarter to $379M.
Based on VHCP Management II's 13F filing for Q4 2019, filed 13 Feb 2020.